Zach Kramer joined Ropes & Gray in 2021 as an associate in the corporate department. He practices primarily in the life sciences and intellectual property transaction groups for a range of private and public clients, with a focus on licensing agreements. During law school, Zach was a notes editor on the Public Contract Law Journal. Additionally, he worked with an advocacy group to promote tort reform across the United States of America. Upon graduation, Zach was made a member of the Order of the Coif to honor his accomplishment of graduating in the top ten percent of his Juris Doctor class. Prior to attending law school, Zach was a personal trainer and volunteered at a youth center.


  • Represented Pfizer in its $6.7 billion acquisition of Arena Pharmaceuticals, a biotechnology company developing potential therapies for the treatment of several immuno-inflammatory diseases.
  • Represented Ginkgo Bioworks in an agreement to acquire biotechnology company Zymergen in an all-stock transaction that values Zymergen at approximately $300 million.
  • Represented HP Inc. in acquisition of Poly Inc. in an all-cash transaction for an implied total enterprise value of $3.3 billion.
  • Represented a global biopharmaceutical company in a collaboration and option agreement with a biotechnology company to discover, develop, and commercialize innovative small molecule drugs against certain oncology and immunology targets.
  • Represented a biotechnology company in obtaining a license to a CRISPR nuclease to discover, develop, and commercialize certain products.
  • Represented a clothing manufacture company in the purchase of certain intellectual property & other assets from various legal persons.
  • Represented Kohlberg & Company portfolio company MarketCast in its add-on acquisition of Research Horizons (d/b/a Phoenix Marketing International), a provider of global marketing research and consulting services.
  • Represented a pharmaceutical company in obtaining an exclusive license to a patient tracking platform from a software company.
  • Represented a U.S.-based software technology company in procuring software to be jointly developed by Asia-based software development entities. 
  • Represented TPG Capital in its approximately $2 billion sale of Immucor, a manufacturer of transfusion and transplantation diagnostic products, to Werfen, a provider of healthcare diagnostic services based in Spain.

Areas of Practice